^
    Back
    Association details:
    Biomarker:HMGB1 positive
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer

    Published date:
    01/13/2021
    Excerpt:
    For endocrine resistant breast cancer, compared with HMGB1 negative patients, HMGB1 positive patients who received CDK4/6 inhibitors treatment benefited more in PFS. HMGB1 serving as a potential biomarker for screening sensitive patients of CDK4/6 inhibitors.
    DOI:
    10.1111/cas.14813